Open in PodwiseOpen

Podcast cover

BioCentury · Business

BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs. For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Episodes

Ep. 310 - Sarepta & What's Next for Gene Therapy. Plus: Leading FDA's CDER

Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days

Ep. 308 - Grand Rounds - Europe Preview

Ep. 307 - How Cancer Regulation is — and isn’t — Changing at FDA

Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences

Ep. 305 - FDA's Future; In Vivo Car T Plays; Psychedelics; CDK2

Ep. 304 - Syncona Reshapes Fund; Lilly's $1B Verve Bet; FDA's 2-Track Future

Ep. 303 - Gene Therapy Safety, Amylin in Obesity & FDA's Future

Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago

Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans

Ep. 300 - Biotech’s $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat

Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs

Ep. 298 - Takeaways from the 25th Bio€quity Europe

Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO

Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights

Ep. 295 - Bio€quity Europe 2025 Preview

Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing

Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs

Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview

Ep. 291 - Grand Rounds - U.S. Preview

Page 5

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise